Liver masses present a relatively common clinical dilemma, particularly with the increasing use of various imaging modalities in the diagnosis of abdominal and other symptoms. The accurate and reliable determination of the nature of the liver mass is critical, not only to reassure individuals with benign lesions but also, and perhaps more importantly, to ensure that malignant lesions are diagnosed correctly. This avoids the devastating consequences of missed diagnosis and the delayed treatment of malignancy or the unnecessary treatment of benign lesions. With appropriate interpretation of the clinical history and physical examination, and the judicious use of laboratory and imaging studies, the majority of liver masses can be characterized noninvasively. Accurate characterization of liver masses by cross-sectional imaging is particularly dependent on an understanding of the unique phasic vascular perfusion of the liver and the characteristic behaviors of different lesions during multiphasic contrast imaging. When noninvasive characterization is indeterminate, a liver biopsy may be necessary for definitive diagnosis. Standard histologic examination usually is complemented by immunohistochemical analysis of protein biomarkers. Accurate diagnosis allows the appropriate selection of optimal management, which is frequently re assurance or intermittent follow-up evaluations for benign masses. For malignant lesions or those at risk of malignant transformation, management depends on the tumor staging, the functional status of the uninvolved liver, and technical surgical considerations. Unresectable metastatic masses require oncologic consultation and therapy. The efficient characterization and management of liver masses therefore requires a multidisciplinary collaboration between the gastroenterologist/hepatologist, radiologist, pathologist, hepatobiliary or transplant surgeon, and medical oncologist.

Initial Clinical Evaluation

A careful review of the personal history and physical examination findings often helps in narrowing the differential diagnoses of liver masses. A history of chronic hepatitis or the features or complications of cirrhosis identifies individuals at risk for hepatocel lular carcinoma (HCC) and intrahepatic cholangiocarcinoma. Similarly, a history of primary sclerosing cholangitis alerts the physician to the significant risk for cholangiocarcinoma and long-term oral contraceptive use predisposes certain women to hepatic adenoma. The family history is also of value in the initial clinical evaluation. A family history of young-onset diabetes mellitus, for example, may predispose to hepatic adenomatosis. Physical complaints such as abdominal pain are often nonspecific but may be the reason for seeking medical attention. Other physical symptoms are more suggestive of the underlying disease, for example, pruritus, dark urine, and pale stools observed in biliary obstruction. A history of constitutional symptoms such as fever may be useful in the diagnosis of hepatic abscesses; fever can also be associated with malignancy. Constitutional features of malignancy also include anorexia, weight loss, and fatigue. The physical examination may show features of chronic liver disease such as spider angiomas, a periumbilical caput medusa indicative of portal hypertension, hepatomegaly, or splenomegaly. Painless jaundice is highly suggestive of a malignancy such as cholangiocarcinoma or pancreatic adenocarcinoma whereas advanced malignant infiltration and some benign masses may be associated with palpable hepatomegaly, which may be nodular in patients with cirrhosis or focal masses.

The history and physical examination are complemented by laboratory tests that may show active hepatitis, a low platelet count caused by chronic liver disease with cirrhosis, portal hypertension and hypersplenism, or hyperbilirubinemia. The use of serum α-fetoprotein (AFP) level in surveillance for HCC is

**Keywords:** Hepatocellular Carcinoma; Focal Nodular Hyperplasia; Hepatic Adenoma; Cholangiocarcinoma; Hepatic Hemangioma; Liver Imaging.
Table 1. Clinical Classification of Liver Mass Lesions

<table>
<thead>
<tr>
<th>Benign mass lesions for which no treatment is needed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic hemangioma</td>
</tr>
<tr>
<td>FNH</td>
</tr>
<tr>
<td>Benign liver cyst</td>
</tr>
<tr>
<td>Focal fat or focal fat sparing</td>
</tr>
<tr>
<td>Benign mass lesions for which treatment or follow-up evaluation is required</td>
</tr>
<tr>
<td>Hepatic adenoma and adenomatosis</td>
</tr>
<tr>
<td>Biliary cystadenoma</td>
</tr>
<tr>
<td>Hepatic abscess</td>
</tr>
<tr>
<td>Echinococcal cysts</td>
</tr>
<tr>
<td>Granulomatous Inflammation</td>
</tr>
<tr>
<td>Inflammatory pseudotumor of the liver</td>
</tr>
<tr>
<td>Malignant mass lesions for which treatment is required if feasible</td>
</tr>
<tr>
<td>HCC</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
</tr>
<tr>
<td>Liver metastases from other primary sites</td>
</tr>
<tr>
<td>Biliary cystadenocarcinoma</td>
</tr>
<tr>
<td>Hepatic angiosarcoma</td>
</tr>
<tr>
<td>Lymphoma</td>
</tr>
</tbody>
</table>

Controversial because of low sensitivity for the detection of early stage disease.\(^2,3\) AFP is well established as a predictor of risk of HCC in individuals with cirrhosis and can be extremely useful for HCC diagnosis in individuals with diffuse HCCs.\(^3\) Although one-time AFP determinations have a high false-positive rate, particularly in patients with chronic hepatitis C virus, trends and patterns in AFP levels can be useful for early diagnosis of HCC.\(^4\) A high AFP level is also prognostic for the outcomes of patients with HCC.\(^5\) The AFP-L3 and des-gamma carboxyprothrombin also predict risk of HCC and are used extensively in Asia, particularly in Japan.\(^6\) However, they are not yet in wide clinical use in Europe or the United States. The carbohydrate antigen 19-9 level is helpful in the diagnosis and prognostic prediction of patients with cholangiocarcinoma.\(^7\) In the absence of acute cholangitis, a carbohydrate antigen 19-9 level greater than 1000 units/mL usually indicates the presence of extrahepatic disease.\(^7\) The carcinoembryonic antigen level is valuable in assessing colorectal cancer metastatic to the liver, and the chromogranin A and 24-hour urine 5-hydroxyindoleacetic acid levels are useful for assessing neuroendocrine carcinomas metastatic to the liver.\(^8,9\) In general, these markers are of value in determining the nature of malignant liver lesions when present, while having a relatively low specificity in the absence of detectable lesions. An increased lactate dehydrogenase level and widespread intra-abdominal lymphadenopathy may be clues to liver infiltration by lymphoma masquerading as primary liver cancer.

Radiologic Imaging Studies Are Critical for Accurate Characterization of Liver Mass Lesions

The radiologic features of liver masses as assessed by liver ultrasonography or by cross-sectional imaging using computed tomography (CT) or magnetic resonance imaging (MRI) are extremely helpful in diagnosis. Specialized imaging studies such as octreotide scans, used in the diagnosis of neuroendocrine tumors, and positron emission tomography scans, used for detection of metastatic disease or cholangiocarcinoma, are also valuable adjuncts for clinical diagnosis and management.

Surveillance for Hepatocellular Carcinoma

For individuals with chronic hepatitis B virus (HBV) infection or cirrhosis from any cause who are at risk for development of HCC, surveillance ultrasonography every 6 months is recommended for early identification of HCCs and is critical for achieving long-term survival (Table 2).\(^2\)

The Use of Multiphasic Cross-Sectional Imaging in the Evaluation of Liver Masses

Cross-sectional imaging with CT or MRI is enhanced by the use of intravenous contrast agents and dynamic multiphasic examination techniques. The liver has 3 distinct phases after intravascular contrast agent is injected via a peripheral vein. The arterial phase occurs 25 to 35 seconds after peripheral contrast injection and is caused by the direct infusion of arterial blood with a high concentration of contrast from the heart through the hepatic artery into the liver. Next, the portal venous phase occurs 60 to 75 seconds after contrast injection as blood from the gastrointestinal tract is collected in the portal vein for processing in the liver. Finally, in the venous phase, blood from the liver is collected into the hepatic veins, which converge to the inferior vena cava for return to the right atrium. The intravascular contrast leaks

Table 2. Recommended High-Risk Population for Screening for HCC

<table>
<thead>
<tr>
<th>Patients with chronic HBV infection (hepatitis B surface antigen positivity)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian men older than age 40</td>
</tr>
<tr>
<td>Asian women older than age 50</td>
</tr>
<tr>
<td>Africans older than age 20</td>
</tr>
<tr>
<td>Patients with a family history of HCC</td>
</tr>
<tr>
<td>Patients with high HBV viral loads</td>
</tr>
<tr>
<td>Patients with evidence of active hepatitis</td>
</tr>
<tr>
<td>Patients with cirrhosis of any cause</td>
</tr>
<tr>
<td>Chronic hepatitis B</td>
</tr>
<tr>
<td>Chronic hepatitis C</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
</tr>
<tr>
<td>Nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>Hereditary hemochromatosis</td>
</tr>
<tr>
<td>Autoimmune hepatitis</td>
</tr>
<tr>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>a-1 antitrypsin deficiency</td>
</tr>
</tbody>
</table>

September 2014 Liver Masses 1415
through the liver sinusoids into the extracellular space and about 3 to 5 minutes after injection, the extracellular contrast reaches equilibrium with the concentration in the vascular system. This is known as the *equilibrium phase*. This unique blood supply to the liver is exploited by contrast imaging techniques because many mass lesions have characteristic patterns of appearance in the arterial, portal venous, and equilibrium phases. Newer contrast agents that are taken up by functioning hepatocytes and excreted into bile, such as disodium gadoxetate (Gd-EOB-DTPA; Eovist; Bayer Corporation, Pittsburgh, PA) and gadobenate dimeglumine (Gd-BOPTA; MultiHance; Bracco Diagnostics Inc, Princeton, NJ), provide further phenotypic characterization of liver masses and are particularly useful in the differentiation of adenomas from focal nodular hyperplasias (FNHs) and the diagnosis of HCC and metastases. The enhancement of hepatocytes with these hepatobiliary contrast agents in the hepatocyte or parenchymal phase typically peaks between 20 and 60 minutes after intravenous injection. Uptake of gadoxetate and gadobenate is believed to occur mainly through cell membrane proteins in the bile canaliculi and ducts, including organic anion transporting polypeptides and multidrug resistance protein. The expression of these proteins is usually suppressed in adenomas and HCCs and lack of the hepatocyte phase enhancement is useful in differentiating them from FNH.

Imaging characteristics on MRI are useful in differentiating HCC from other hepatic lesions. The T2-weighted sequence is sensitive to alterations in water content and pathologic tissues appear brighter than normal tissues. Most HCCs show high signal intensity on T2-weighted images compared with benign lesions such as adenomas and FNHs. The in-phase and opposed-phase sequences in which regions of fat deposition show characteristic signal loss in the opposed phase can be useful in differentiating HCC from focal fat deposition or focal fat sparing. Diffusion-weighted imaging (DWI) highlights the areas of restricted diffusion and is sensitive to focal abnormalities. Malignant lesions show restricted diffusion on DWI and appear brighter. However, this finding lacks sufficient specificity to be the sole diagnostic criterion in routine clinical practice. Moreover, combining DWI with contrast-enhanced MRI provides high accuracy for the detection and characterization of HCCs.

Recent advances in CT provide higher spatial and temporal resolution for the evaluation of liver tumor hemodynamics, while also providing 3-dimensional or 4-dimensional imaging for treatment planning. Perfusion CT provides quantitative information about arterial perfusion in HCC, allowing the evaluation of tumor angiogenesis and response to therapy. Dual-energy CT (performed with 2 different energy spectra) improves detection and assessment of hypervascular tumors. Magnetic resonance elastography and acoustic radiation force impulse imaging are currently under investigation and may potentially be useful techniques in the characterization of liver masses.

**Needle Biopsy, Histopathology, and Immunohistochemical Studies**

Needle biopsies combined with histopathology and immunohistochemistry can be invaluable for characterizing liver masses. For suspected malignant masses, consideration should be given to whether a biopsy is necessary. Highly specific radiologic criteria have been established for the noninvasive diagnosis of HCC. These have been useful in reducing the need for biopsy in patients with cirrhosis who are eligible for liver transplantation and are at the highest risk for needle tract seeding and tumor recurrence owing to the immunosuppression after liver transplantation. There is an approximately 10% false-negative rate with biopsy of small liver lesions as a result of difficulties with accurately targeting the lesion. On the other hand, biopsy is encouraged for diagnosis of patients with advanced disease who are not surgical resection candidates because newer molecular analyses may help determine the most appropriate chemotherapeutic agents. Overall, biopsies of malignant lesions carry a low risk of tumor seeding for suspected HCCs. However, for patients with suspected hilar cholangiocarcinomas under consideration for potentially curative resection or liver transplantation, transperitoneal fine-needle aspiration biopsy has been shown to be associated with a higher rate of peritoneal metastases.

**Endoscopic, Interventional Radiologic, and Molecular Pathologic Techniques for Evaluation of Liver Mass Lesions**

Endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, and endoscopic ultrasonography allow access to detailed imaging of the biliary system and the hepatic hilum, pancreas, and associated lymph nodes. Ancillary techniques such as cholangioscopy, bile duct biopsy and brushing, lymph node sampling by fine-needle aspiration, and cytologic and fluorescence in situ hybridization examination of cells obtained from pancreatobiliary strictures or lymph nodes can further enhance the diagnostic armamentarium.

**Clinical and Radiologic Features of the Common Liver Mass Lesions**

**Cavernous Hemangioma**

**Epidemiology.** Cavernous hemangiomas are the most common benign liver lesions. Autopsy studies show that they occur in up to 7% of individuals, more commonly in women than in men.

**Pathogenesis and morphology.** Hemangiomas are congenital malformations in the vascular structure of
the liver and are usually solitary. They are grossly well-circumscribed and appear reddish-brown. Histologically, they have varying sized blood-filled vascular spaces lined by flattened endothelial cells (Figure 1).

**Imaging features.** Hemangiomas typically have increased echogenicity on ultrasound. Hemangiomas are usually hypodense or isodense to liver parenchyma on unenhanced CT. At MRI, they are characteristically hyperintense to liver on T2-weighted images and have moderately low signal intensity on T1-weighted MR images. In multiphasic CT or MRI studies, they show peripheral nodular enhancement in the arterial phase with progressive centripetal filling-in toward the center of the mass in the portal venous and delayed phases²⁷⁻³² (Figure 2). The density of enhancement is similar to the contrast in the aorta in all phases.³³ Characteristic findings on ultrasound, CT, and MRI are diagnostic of hemangiomas. Atypical hemangiomas and a significant number of small hemangiomas may show flash (immediate homogeneous) arterial phase enhancement. Large hemangiomas may be heterogeneous in appearance owing to thrombosis, fibrosis, or calcification,²⁷⁻²⁹ especially on MRI, and may not show complete filling-in.³⁰⁻³³ The diagnosis of an atypical hemangioma can be confirmed by showing stability on follow-up imaging; rarely other tests or biopsy are required.

**Management.** Hemangiomas do not generally grow or suffer complications such as hemorrhage, rupture, or malignant transformation. Because of their benign nature, there is no indication for therapy unless they are symptomatic, causing pain from a subcapsular location in the liver, or are so large that they compromise liver synthetic function.

**Simple Hepatic Cyst**

**Epidemiology.** Simple liver cysts are also very common in the liver, occurring in about 5% of individuals. They are also more common in women than men.

**Morphology.** Simple cysts are lined by cuboidal to low columnar biliary epithelium and a fibrous wall.

**Imaging features.** Cysts are characterized by their round or oval shape and barely visible wall on imaging.²⁴ On liver ultrasound, cysts typically show through transmission with no echoes and a sharp distant border with shadowing. In multiphasic CT or MRI studies, they show a water density signal that does not enhance during the multiphasic contrast examination (Figure 3). The clear liquid gives a bright T2 signal on MRI.³⁵ Septations within simple cysts are uncommon. Thickened or nodular septa and an enhancing rim of a cystic lesion should raise the suspicion of an infected cyst or a cystic neoplasm.

**Management.** Simple cysts usually do not grow or cause complications. A case series of several cysts detected antenatally showed that of the 10 simple cysts that were followed up postnatally, 9 remained static or regressed, suggesting that the natural history of simple cysts is benign.²⁶ Rarely, a large cyst will cause biliary obstruction, which can be treated by alcohol sclerosis, or if needed by laparoscopic or open surgical cyst fenestration.
Polycystic Liver Disease

**Epidemiology.** Polycystic liver disease is diagnosed when 20 or more cysts, ranging from a few millimeters wide to several centimeters, are present. The disease is relatively rare, typically presenting as one of two phenotypes: the autosomal-dominant or recessive polycystic kidney disease or autosomal-dominant polycystic liver disease, with the former predominantly a renal disease with the possibility of liver cysts and the latter manifesting solely as a hepatic disease. The disease process is thought to be caused by defective bile duct formation and arrangement.

**Imaging features.** Imaging features are as described earlier for simple liver cysts, except for the multiplicity of lesions seen, which may replace the liver parenchyma almost completely.

**Management.** Unlike simple hepatic cysts, the multitude of cysts in this condition may interfere with liver function and are quite often symptomatic. Treatment options include aspiration, sclerotherapy, or segmental liver resection. In some cases, a liver transplant may be indicated. Octreotide and related analogs are in clinical trials for treatment of polycystic liver disease.

Focal Nodular Hyperplasia

**Epidemiology.** FNHs are relatively common benign liver masses. They are present in the livers of approximately 4% of individuals, more commonly in women than in men. FNHs are generally solitary but can be multiple.

**Pathogenesis, morphology, and molecular pathology.** FNHs are thought to develop around a preexisting arterial malformation caused by a hyperplastic growth response to parenchymal blood flow. Grossly, FNHs are well circumscribed but nonencapsulated and show a central fibrous scar on cut section. They are characterized histologically by hepatic parenchyma arranged in incomplete nodules separated by fibrous tissue that contains abnormal thick-walled vessels, bile ductular proliferation, and chronic inflammation.

**Imaging features.** FNHs are composed of normal hepatocytes and behave similar to a regenerative mass of hepatocytes. They lack a terminal central hepatic vein and characteristically show capillarization of sinusoids derived from a feeding artery that is usually larger than normal. On ultrasound, FNHs may show very slight changes in echogenicity compared with the surrounding parenchyma and usually appear hypoechoic or isoechoic and slightly inhomogeneous because of the central scar. FNHs usually are isodense with the surrounding liver on CT and isointense on MRI. This feature may make them undetectable on unenhanced imaging and has earned them the label *stealth lesions*. They are fairly homogeneous except for the central scar when it is present, which typically is hypodense on CT and bright on T2-weighted MRI. A central scar, when present, is quite specific. In multiphasic CT or MRI studies, FNHs typically show rapid homogeneous uptake of contrast in the early arterial phase with rapid return to near-normal enhancement in the portal venous and delayed phases. With MRI contrast agents such as gadoxetate disodium (Eovist) or gadobenate dimeglumine (MultiHance) that have both renal and biliary excretion, FNHs show active hepatocyte uptake and look similar to or brighter than the surrounding liver tissue in the hepatocyte phase of imaging.

**Management.** Most FNHs do not expand or develop complications such as hemorrhage, rupture, or malignant transformation. Because of their benign nature, there is no indication for therapy unless they are symptomatic from a subcapsular location in the liver.

Hepatic Adenoma and Adenomatosis

**Epidemiology.** Hepatic adenomas are relatively uncommon benign liver masses most commonly seen in
women, but also increasingly found in men, particularly those with the metabolic syndrome. There are different subtypes of hepatic adenomas differentiated by their histologic, genetic, and radiologic phenotypes and by their epidemiologic characteristics. Major etiologic factors for hepatic adenomas include oral contraceptive use, anabolic steroids in men, the metabolic syndrome, and excessive alcohol use. Newer-generation contraceptive pills with lower estrogen content likely are associated with a lower risk of hepatic adenomas. Despite that, the overall incidence of hepatic adenomas has not decreased. This perhaps can be explained by the increasing rates of obesity worldwide and an associated increase in the metabolic syndrome, with a subset of those patients being diagnosed with hepatic adenomas, particularly the inflammatory and telangiectatic variant. This suggests that obesity and metabolic syndrome increase the risk of developing adenomas. The presence of multiple hepatic adenomas in the liver, typically greater than 5 or greater than 10 adenomas, depending on the particular definition, is referred to as hepatic adenomatosis. Adenomatosis is associated with glycogenosis type Ia or III, Klinefelter syndrome, familial diabetes, or familial adenomatosis. Clinically, hepatic adenomas are characterized by their responsiveness to estrogen and their tendency toward intratumoral hemorrhage with scarring and, rarely, hepatic rupture with hemoperitoneum. Adenomas also have a small, but real, risk of malignant transformation into HCCs.

**Pathogenesis, morphology, and molecular pathology.** Adenomas may be single or multifocal. They are generally round, well circumscribed, and bulge on cut section. Microscopically, they show benign normal-appearing hepatocytes arranged in sheets or cords with naked or unaccompanied arteries and an absence of normal portal tracts. The normal cell plate architecture is preserved within the lesion and the cell plates are usually only 2 cells thick. Mitotic figures are absent or extremely rare (Figure 5). Adenomas associated with anabolic steroids

---

**Figure 4.** Focal nodular hyperplasia (white arrows) seen as isointense to hypointense liver parenchyma on T2- and T1-weighted images with a central T2 hyperintense scar. During the arterial phase there is intense homogeneous enhancement of the mass, which becomes isointense in portal venous and delayed phases. Positive uptake is seen in the hepatocyte phase, which is characteristic. The gross picture shows a well-circumscribed lesion showing the characteristic central scar (arrow, bottom left panel). The microscopic section (H&E stain, ×40) shows a scar in the center (long arrow, bottom right panel) with a few thick-walled vessels subdividing the lesion into smaller nodules. There is also steatosis within the hepatocytes (short arrow, bottom right panel). T1W, T1-weighted; T2W, T2-weighted.
show pseudogland formation with bile plugs, peliosis hepatis, and nuclear atypia. Based on genetic and immunohistochemical analyses, hepatic adenomas are subclassified into the following: (1) inflammatory hepatic adenomas, 60% of which are characterized by activating in-frame deletions of the interleukin-6 signal transduction protein gp130 and expression of the inflammation-associated C-reactive protein and serum amyloid A protein; (2) hepatocyte nuclear factor 1α-inactivated hepatic adenomas, which are steatotic and do not express liver fatty acid binding protein; hepatocyte nuclear factor 1α gene mutations are also associated with familial maturity-onset diabetes of the young and hepatic adenomatosis; (3) β-catenin–activated hepatic adenomas, which overexpress glutamine synthetase in the cytoplasm and show aberrant expression of β-catenin in the nucleus; and (4) an indeterminate subgroup.\(^63,64\) Characterizing the different adenoma subclasses carries prognostic significance. β-catenin–expressing adenomas have an increased risk of malignant transformation and quite often are indistinguishable from well-differentiated HCCs. Similarly, inflammatory hepatic adenomas may carry β-catenin mutations and hence are at risk for malignant transformation.\(^63\) Phenotypic and genetic characterizations are therefore increasingly important in the management of adenomas.

**Imaging features.** The appearance of hepatic adenomas is variable and dependent on the composition of the adenoma. Adenomas can have variable amounts of fat and may have intraslesional hemorrhage and necrosis. Small adenomas are frequently mistaken for FNHs because they typically show rapid homogeneous uptake of contrast in the early arterial phase of multiphasic CT or MRI studies with rapid return to near-normal enhancement in the portal venous and venous phases\(^65\) (Figures 5 and 6). Larger adenomas develop intratumoral hemorrhage, necrosis, and subsequent scarring, leading to a heterogeneous appearance on imaging.\(^35,65,66\) The risk of hemorrhage is higher in lesions larger than 5 cm. The heterogeneous appearance and arterial phase enhancement of adenomas frequently mimics HCCs. Because of their preponderance of neoplastic hepatocytes and absence of biliary elements, hepatic adenomas usually show no uptake of contrast agents with hepatobiliary excretion such as gadoxetate disodium (Eovist) or gadobenate dimeglumine (MultiHance) and consequently look darker than the surrounding liver tissue in the delayed hepatobiliary phase. This is an important feature in distinguishing hepatic adenomas from FNHs (Figure 6). However, a minority of hepatic adenomas, particularly the inflammatory adenoma subtype, show uptake of Eovist.\(^67,68\) Correlation with risk factors such as oral contraceptive use helps in determining the correct diagnosis. Follow-up imaging may show interval changes of hemorrhage or necrosis in adenomas, whereas FNHs generally tend to be stable over time.

**Management.** Hepatic adenomas are generally estrogen-responsive and can grow or suffer complications such as hemorrhage, rupture with pain or hemoperitoneum, or malignant transformation. Most adenomas have a benign natural history, with a low risk of hemorrhage or transformation. Surgical resection is recommended for high-risk adenomas, defined as lesions 5 cm or larger in size or increasing in size over time, adenomas
with evidence of internal hemorrhage, adenomas occurring in men, which have increased malignant risk, those with positive nuclear β-catenin immunohistochemical staining, and those occurring in older women with no history of use of oral contraceptives. For low-risk adenomas less than 5 cm in size occurring in young females on oral contraceptive pills, the recommendations are to discontinue use of oral contraceptive pills, switch to an alternative means of birth control, and perform intermittent surveillance imaging. Because of the high estrogen loads associated with pregnancy, females desiring pregnancy should have surgical resection of large adenomas, however, small adenomas can be managed conservatively with intermittent ultrasound imaging during pregnancy. Adenomas that are symptomatic because of their large size or subcapsular location in the liver should be resected. Radiofrequency ablation can be used as an alternative to surgical resection in patients with high surgical risk owing to medical comorbidities.

**Focal Fat Deposition or Fat Sparing**

**Epidemiology.** With the gradually increasing body mass index of people worldwide, particularly in North America and Europe, it is common for individuals to develop regions of focal fatty infiltration in the liver, or alternatively, a liver that is infiltrated diffusely with fat, except for regions of focal fat sparing. Pathogenesis, morphology, and molecular pathology. Areas of focal fat typically show macrovesicular steatosis affecting multiple contiguous acini that still have normal portal areas and central veins.

**Imaging features.** Diffusely increased echogenicity of the fatty liver is characteristic on ultrasonography. Focal fat is also hyperechoic to the normal liver parenchyma on ultrasound. Fat reduces the density of the liver on CT; focal fat deposition appears hypodense to the normal liver and areas of fat sparing appear hyperdense to the surrounding fatty liver. Fatty liver classically shows loss of signal in opposed-phase MRI compared with in-phase images. Focal fat deposition or fat sparing typically occur in the gallbladder fossa, adjacent to the falciform ligament and the periportal region, all of which may be supplied by aberrant systemic veins and do not receive much portal blood. Generally, these lesions do not have a well-defined border or cause any mass effect and the normal blood vessels course through them. Nodular fat sparing can be problematic and may require biopsy for confirmation.

**Management.** There is no specific treatment needed for focal fat or focal fat sparing, unless the patient has steatohepatitis. Focal fat often will resolve if the patient loses weight.

**Hepatic Abscesses**

**Epidemiology.** Hepatic abscesses can be caused by bacterial or amebic infection. Pyogenic bacterial liver abscesses usually are caused by rupture or leak of the bile duct or bowel. They may be associated with biliary stenting, biliary instrumentation, or transarterial chemotherapy of tumor nodules. There is an increased risk of pyogenic abscess in patients with diabetes mellitus. Amebic liver abscesses occur in countries with...
endemic amebiasis and are decreasing in incidence in North America.73

Pathogenesis, morphology, and molecular pathology. Abscesses related to biliary sources usually are caused by enteric gram-negative bacteria or enterococci; those from other intestinal sites frequently have mixed aerobic and anaerobic flora. Abscesses may be single or multiple and are more common in the right lobe. They range in size from microscopic to larger than 3 cm. Microscopically, there is a central area of suppurative necrosis and inflammation surrounded by varying degrees of fibrosis and organizing inflammation. Klebsiella pneumoniae is the frequent cause of a distinct new invasive syndrome of liver abscesses in Asia and increasingly globally.74

Imaging features. The imaging features of hepatic abscesses are dependent on the evolution of the abscess. At earlier stages, abscesses usually are semisolid and irregular, with areas of necrosis, and therefore show variable enhancement. Mature abscesses have a large central necrotic area and a variable rim of granulation tissue and capsule comprising hepatocytes and fibrous tissue. Imaging of early stage abscesses may show poorly defined masses with heterogeneous enhancement; this changes to a well-defined rounded mass when the abscess is mature. By ultrasonography, mature abscesses are not as completely free of echoes as simple hepatic cysts, but nevertheless do not have blood vessels or bile duct structures running through them.75,76 On CT, pyogenic liver abscesses appear as loculated single or multiple lesions with heterogeneous and variable thickness rim enhancement, whereas amoebic liver abscesses tend to be single with a thin enhancing rim and surrounding hypodensity referred to as the halo sign.77,78 Mature abscesses usually do not show internal enhancement. They are bright on T2-weighted MRI and show restricted diffusion on DWI. Pyogenic liver abscesses may be associated with biliary obstruction.77 Invasive K pneumoniae liver abscess syndrome is associated with metastatic infections at other sites, including the lungs, genitourinary system, and eyeball79 (Figure 8).

Management. Suspected pyogenic liver abscesses should be aspirated for aerobic and anaerobic cultures. A drain should be left in abscesses larger than 3 cm. Empiric antibiotic therapy should be initiated and modified once culture results become available. Antibiotic therapy should be continued for at least 4 to 6 weeks.80 Multiple, large, or loculated abscesses may require surgical drainage. Surgery also may be required to treat the underlying cause of the abscess.

Amebic liver abscesses often do not require aspiration; aspirates have the typical appearance of “anchovy paste.”81 Catheter drainage is more effective for large abscesses.82,83 Antiamebic treatment is with metronidazole or tinidazole for 7 to 10 days, followed by a luminal agent such as paromomycin or diiodohydroxyquin.84

Hepatocellular Carcinoma

Epidemiology. HCCs usually develop in the context of cirrhosis caused by chronic HBV or hepatitis C virus
infection, alcohol, or nonalcoholic steatohepatitis. There are more than 700,000 cases of HCC worldwide each year, and it is the second most common cause of death from cancer. Although the prevalence of chronic HBV and hepatitis C virus infection are expected to peak and begin decreasing in the next several years as a result of improvements in prevention, diagnosis, and treatment, it is anticipated that there will be an increase in cases of HCC owing to nonalcoholic steatohepatitis. Smaller proportions of HCCs are caused by hereditary hemochromatosis, primary biliary cirrhosis, and autoimmune hepatitis. Dietary exposure to fungal aflatoxins, cigarette smoking, and diabetes are also important risk factors.2

Pathogenesis, morphology, and molecular pathology. HCCs are thought to arise as a consequence of premature hepatocyte senescence caused by repeated cycles of cell injury, regeneration, and repair, occurring in an inflammatory environment that leads to genetic and epigenetic aberrations. HCCs show significant molecular heterogeneity; a substantial percentage of HCCs have mutations in the promoter of the telomerase reverse transcriptase gene, in the tumor protein p53 and beta catenin genes, and in genes regulating chromatin remodeling.85,86 At least 5 molecular subclasses have been identified thus far, including a proliferative subclass characterized by phosphatidylinositol 3 kinase/Akt kinase activation, a beta catenin mutated subclass, interferon-related, polysomy 7, and undefined classes, however, they are not used routinely in clinical practice.87 Most HCCs in the United States arise within a cirrhotic liver. Microscopically, HCC cells resemble normal hepatocytes to a variable extent in well to moderately differentiated tumors. The tumor is characterized by naked or unaccompanied arteries, the absence of normal portal tracts, and hepatic cord thickness more than 3 cells thick, which can be highlighted by reticulin staining. Mitoses usually are present (Figure 9). Histologic patterns of HCC include trabecular (the most common pattern), acinar (pseudoglandular), solid, and scirrhous patterns. These patterns do not appear to have prognostic significance. Immunohistochemical stains such as HepPar-1, glypican-3, and polyclonal carcinoembryonic antigen level are useful for confirming the diagnosis of HCC.88

Imaging features. HCCs usually develop from dysplastic nodules and are characterized by increased arterial vascularization and progressive loss of the portal venous blood supply that supplies regenerative and dysplastic nodules. These features produce a
characteristic pattern of arterial phase hyperenhancement followed by portal venous or delayed phase washout (washout refers to relative loss of enhancement compared with that of the surrounding liver parenchyma) on multiphasic CT or contrast MRI. In new lesions larger than 1 cm in a cirrhotic liver, this pattern is diagnostic for HCC and is considered a “radiological hallmark of HCC” (Figure 9). Smaller lesions often do not show high arterial phase enhancement. Distinct hypointensity in the hepatobiliary phase of imaging with Eovist increasingly is recognized as a diagnostic feature of HCC. However, a small proportion of HCCs may show uptake of Eovist and appear isointense or hyperintense to the liver in the hepatobiliary phase. HCCs often show decreased T1 signal, increased T2 signal, and restricted DWI on MRI; these features can be used to identify small indeterminate HCCs with atypical enhancement or washout characteristics. Hyperintensity on DWI has been proposed as a new imaging criterion for HCC. Other useful features are the presence of focal fat within the lesion, an internal mosaic appearance; vascular invasion, particularly of the portal vein with tumor thrombus formation; and interval growth of 50% or more on serial imaging follow-up evaluation obtained at a less than a 6-month interval. Imaging features of HCCs can vary if the lesion was previously treated and knowledge of the prior appearance is useful for assessment of treatment response and to detect recurrence. Supportive laboratory findings include a raised or increasing trend of serum AFP level.

**Management.** Management of HCC requires a multidisciplinary approach and is dependent on the number, size, and location of HCC masses, as well as the age, performance status, comorbidities, and liver function of the patient. Of the numerous prognostic staging systems proposed, the Barcelona Clinic Liver Cancer system has been widely accepted, being endorsed by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. The system incorporates tumor staging, functional status, and cancer-related symptoms into a 5-stage system (very early or stage 0, early or stage A, intermediate or stage B, advanced or stage C, and end-stage or stage D), with therapeutic guidelines for each stage. Patients with acceptable liver function who are candidates can be treated with surgical resection, if this is technically feasible. Patients with cirrhosis who meet the Milan criteria: 1 mass 5 cm or less in size or 2 or 3 lesions 3 cm or less in size, are listed for liver transplant. Lesions 3 cm or less in size that are not amenable to resection or transplant can be treated with radiofrequency, laser, or microwave ablation or percutaneous alcohol injection. Intermediate-stage disease usually is treated with transarterial chemoembolization or radioembolization. The current standard of care for advanced-stage HCC is sorafenib. Patients with poor performance status or Child–Pugh class C cirrhosis have poor survival rates and receive symptomatic care only.

**Biliary Tract Cancers**

**Epidemiology.** Biliary tract cancers include cholangiocarcinomas and gallbladder cancers. Cholangiocarcinomas are malignancies of the intrahepatic or extrahepatic biliary tract. Intrahepatic cholangiocarcinomas usually present as mass lesions within the liver, whereas extrahepatic cholangiocarcinomas present with biliary obstruction at the hilum of the liver (perihilar cholangiocarcinomas) or within the common bile duct (distal cholangiocarcinomas). The major risk factors for cholangiocarcinoma are biliary tract diseases including primary sclerosing cholangitis, liver fluke infestations with *Opisthorchis viverrini* or *Clonorchis sinensis*, and choledochal cysts, cirrhosis, diabetes, and smoking. Although the incidence of extrahepatic cholangiocarcinomas has remained stable over time, there has been a 7-fold increase in the incidence of intrahepatic cholangiocarcinomas from 0.3 per 100,000 person-years to 2.1 per 100,000 person-years over the past 2 decades. The cause of this increase is unknown, but increased exposure to environmental toxins in industrial countries has been suggested. Concomitantly, the incidence of gallbladder cancer has decreased by approximately 50% from 4.0 per 100,000 person-years to 2.2 per 100,000 person-years, perhaps owing in part to increasing rates of cholecystectomy for gallstone disease.

**Pathogenesis, morphology, and molecular pathology.** A common thread in the etiologic factors for cholangiocarcinoma are inflammatory conditions of the liver and biliary tract, and factors such as diabetes and smoking, which contribute to genomic instability through oxidative stress and faulty DNA repair mechanisms. These tumors can present as a single mass, a large mass with satellite nodules, or multiple nodules within the liver. Microscopically, cholangiocarcinomas usually are well-differentiated adenocarcinomas and resemble other glandular carcinomas of extrahepatic origin. The diagnosis of cholangiocarcinoma often depends on clinical and radiologic exclusion of other primary sites. Cholangiocarcinomas are often scirrhous, with islands of malignant cells surrounded by dense stroma, which can make cytologic diagnosis difficult. When cholangiocarcinomas develop in bile duct strictures, the demonstration of chromosomal polysomy in cytologic specimens using fluorescence in situ hybridization has proven more sensitive than cytology, while maintaining high specificity. Molecular analyses of cholangiocarcinomas show mutations in the Kirsten rat sarcoma viral oncogene, tumor protein p53, isocitrate dehydrogenase 1 or 2, V-RAF murine sarcoma viral oncogene homolog B1, epidermal growth factor receptor, MET protooncogene, and phosphatidylinositol 3-kinase catalytic alpha genes.

**Imaging features.** Intrahepatic cholangiocarcinomas usually appear as solid masses that are hypointense in precontrast images, gradually accumulating a moderate
amount of contrast through the arterial, portal, and venous phases of CT or MRI (Figure 10). The accumulation of contrast in the delayed phase is heterogeneous or central related to the scirrhous tissue in the cholangiocarcinoma and distinct from hemangiomas that show complete and homogeneous filling. A thick rim of enhancement in the delayed phase is characteristic of cholangiocarcinomas and helps in differentiating them from HCCs. Characteristically, hilar cholangiocarcinomas initially will occlude the bile duct to one lobe of the liver and encase the portal vein supplying that lobe. This leads to lobar atrophy and compensatory hyper trophy of the contralateral hepatic lobe. Progression of the tumor across the hilar bifurcation then results in occlusion of both the right and left bile ducts, resulting in the typical atrophy–hypertrophy complex. Hilar cholangiocarcinomas lead to dilatation of the intrahepatic bile ducts, while distal extrahepatic cholangiocarcinomas lead to dilatation of the entire biliary tree.

Management. The management of intrahepatic cholangiocarcinomas is surgical resection if technically feasible. Unfortunately, because intrahepatic cholangiocarcinomas typically occur in patients without known risk factors, they often are large and unresectable at the time of diagnosis. Palliative chemoembolization or radioembolization and/or chemotherapy are the most frequent treatments used. Patients with intrahepatic cholangiocarcinomas are not candidates for liver transplantation because of their high propensity for metastasis.

A proportion of perihilar or extrahepatic cholangiocarcinomas can be resected. Unresectable hilar tumors with a radial diameter of up to 3 cm and no evidence of extrahepatic spread qualify for a protocol of external beam radiotherapy combined with radiosensitizing chemotherapy, brachytherapy with endoscopically placed iridium-192 beads, maintenance chemotherapy, staging laparoscopic surgery to rule out the interval development of metastases, and orthotopic liver transplantation. This protocol has been shown to achieve a 5-year survival rate of 53%.

Liver Metastases

Epidemiology. Liver metastasis is uncommon in the cirrhotic liver. In contrast, in noncirrhotic livers, metastases from other primary sites are the most common malignant liver masses and are most frequently from colorectal, gastric, pancreatic, or intestinal primary sites, including neuroendocrine tumors, as well as renal cell carcinomas and melanomas. Therefore, patients without cirrhosis should be evaluated carefully for a possible...
primary site. This is facilitated by special immunohistochemical stains performed on biopsy specimens of the liver masses.

Pathogenesis, morphology, and molecular pathology. The pathogenesis, morphology, and pathology are dependent on the primary tumor type.

Imaging features. Metastases have variable imaging features, but typically are hypoechoic on ultrasound, hypodense on CT, and hypointense on MRI during the portal venous phase, compared with the surrounding liver parenchyma. Some metastases show arterial phase rim enhancement with washout in the portal venous phase. Hypervascular metastases that show relatively homogeneous enhancement in the arterial phase typically originate from renal cell, breast, thyroid, melanoma, and neuroendocrine tumors. Hypovascular metastases are usually from pancreas and gastrointestinal tract adenocarcinomas. The most specific feature of metastases is washout in the delayed phase.

Management. The specific management of liver metastases is dependent on the primary tumor type and the extent of metastatic disease. Appropriate therapies may include systemic therapy, surgical resection, local ablation, or locoregional radioembolization, chemotherapy, or locoregional radioembolization, chemoembolization, or bland embolization.

References


Reprint requests
Address requests for reprints to: Lewis R. Roberts, MB ChB, PhD, Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905. e-mail: roberts.lewis@mayo.edu; fax: (507) 284-0762.

Acknowledgment
The authors thank Esha Baichoo, MD, for critical revision of the manuscript and editorial assistance.

Conflicts of interest
The authors disclose no conflicts.